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ABSTRACT
The Nairovirus genus of the Bunyaviridae family contains serious human and animal pathogens classified within multiple sero-
groups and species. Of these serogroups, the Crimean-Congo hemorrhagic fever virus (CCHFV) serogroup comprises sole mem-
bers CCHFV and Hazara virus (HAZV). CCHFV is an emerging zoonotic virus that causes often-fatal hemorrhagic fever in in-
fected humans for which preventative or therapeutic strategies are not available. In contrast, HAZV is nonpathogenic to humans
and thus represents an excellent model to study aspects of CCHFV biology under conditions of more-accessible biological con-
tainment. The three RNA segments that form the nairovirus genome are encapsidated by the viral nucleocapsid protein (N) to
form ribonucleoprotein (RNP) complexes that are substrates for RNA synthesis and packaging into virus particles. We used
quantitative proteomics to identify cellular interaction partners of CCHFV N and identified robust interactions with cellular
chaperones. These interactions were validated using immunological methods, and the specific interaction between native
CCHFV N and cellular chaperones of the HSP70 family was confirmed during live CCHFV infection. Using infectious HAZV, we
showed for the first time that the nairovirus N-HSP70 association was maintained within both infected cells and virus particles,
where N is assembled as RNPs. Reduction of active HSP70 levels in cells by the use of small-molecule inhibitors significantly re-
duced HAZV titers, and a model for chaperone function in the context of high genetic variability is proposed. These results sug-
gest that chaperones of the HSP70 family are required for nairovirus replication and thus represent a genetically stable cellular
therapeutic target for preventing nairovirus-mediated disease.
IMPORTANCE
Nairoviruses compose a group of human and animal viruses that are transmitted by ticks and associated with serious or fatal
disease. One member is Crimean-Congo hemorrhagic fever virus (CCHFV), which is responsible for fatal human disease and is
recognized as an emerging threat within Europe in response to climate change. No preventative or therapeutic strategies against
nairovirus-mediated disease are currently available. Here we show that the N protein of CCHFV and the related Hazara virus
interact with a cellular protein, HSP70, during both the intracellular and extracellular stages of the virus life cycle. The use of
inhibitors that block HSP70 function reduces virus titers by up to 1,000-fold, suggesting that this interaction is important within
the context of the nairovirus life cycle and may represent a potent target for antinairovirus therapies against which the virus can-
not easily develop resistance.
The Bunyaviridae family of trisegmented negative-sense RNAviruses comprises five genera, namely, Orthobunyavirus, Han-
tavirus, Nairovirus, Phlebovirus, and Tospovirus (1). The Nairovi-
rus genus contains several serogroups, one of which is the
Crimean-Congo hemorrhagic fever virus (CCHFV) serogroup,
with sole members CCHFV and the genetically distinct Hazara
virus (HAZV) (2) that are formally grouped under the same spe-
cies name of CCHFV. CCHFV is a risk group 4 human pathogen,
responsible for a devastating disease for which preventative or
therapeutic measures do not exist (3). Transmission of CCHFV to
humans often occurs by the bite of infected ixodid ticks of the
Hyalomma genus (4), and the human case-fatality rate can exceed
60% (5). In recent years, the occurrence of CCHFV-mediated dis-
ease has been newly reported in many Mediterranean countries
(3), likely as a consequence of the increasingly broad habitat and
population size of its tick vector, with the increases possibly oc-
curring in response to climate change (6). CCHFV is now recog-
nized as a potential threat to human health in the densely popu-
lated regions of Northern Europe (7). In contrast, HAZV has not
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been associated with serious human disease and is classified as a
risk group 2 pathogen. HAZV infection of type 1 interferon recep-
tor-deficient mice shares clinical features of CCHFV-mediated
disease in humans and represents an accessible CCHFV infection
model (8). Taken together, these findings suggest that HAZV is a
useful surrogate that can be used to study the molecular, cellular,
and disease biology of the highly pathogenic CCHFV, as well as of
other nairoviruses responsible for serious human and animal dis-
eases. Such nairoviruses include Erve virus, which causes “thun-
derclap” headaches in humans (9), and Nairobi sheep disease
virus, which is responsible for hemorrhagic gastroenteritis in live-
stock such as sheep and goats (10).
The nairovirus genome comprises three strands of negative-
sense RNA that are named small (S), medium (M), and large (L),
reflecting their relative sizes. The S segment encodes the nucleo-
capsid (N) protein, the M segment encodes the envelope glyco-
proteins Gn and Gc, and the L segment encodes the viral RNA-
dependent RNA polymerase (RdRp). As with all bunyaviruses, the
nairovirus genome and antigenome are encapsidated by multiple
copies of the viral N protein to form a ribonucleoprotein (RNP)
complex. This N-RNA association is thought to be critical for the
virus replication cycle, and only in the form of the RNP can the
CCHFV genome be transcribed and replicated (11). The forma-
tion of the nairovirus RNP is also dependent on the ability of the N
protein to interact with itself to form extended oligomers, and
details of this interaction have been revealed at the atomic level by
the CCHFV N protein crystal structure, reported from several
groups, including us (11–13). More recently, the solution of the
HAZV N protein crystal structure by others and ourselves (14, 15)
reveals a high degree of structural similarity with CCHFV N, pro-
viding further support for the use of HAZV as a model for
CCHFV, in particular for functions related to their N proteins.
In addition to these interactions with viral RNP components,
bunyavirus N proteins are known to interact with multiple cellular
proteins, resulting in changes to a range of cellular functions such
as disruption of host cell signaling pathways (16, 17), cellular
mRNA cap binding (18, 19), and the recruitment of host cell
translation machinery to enhance viral protein expression (20,
21). In comparison to the information available regarding bunya-
viruses from other genera, less is known about the cellular inter-
acting partners specific to the nairovirus N protein. Two interact-
ing cellular proteins have previously been identified, namely, actin
and the large GTPase MxA (22, 23). Although the functional con-
sequences of these interactions within the virus replication cycle
have not been fully elucidated, those studies showed that N was
capable of interacting with cellular proteins.
Identification of interactions between host and virus compo-
nents is important as it holds the potential to result in develop-
ment of novel disease prevention strategies that focus on either
host or viral targets. Therapeutic strategies that target host cell
components possibly reduce the likelihood of resistance develop-
ing due to the relatively low rate of cellular DNA genetic change
compared to the more rapid virus evolution. This is especially
pertinent in the case of RNA viruses such as CCHFV, which have
high mutation rates due to their error-prone RNA polymerases
(24).
In order to better understand the interaction between the nai-
rovirus N protein and the host cell, we performed a mass spec-
trometry-based analysis of its coprecipitating cellular proteins. In-
dependent validation by immunological means revealed that
cellular chaperones, particularly those of the HSP70 family, were
abundant interactors. We showed that this interaction was main-
tained throughout both the intracellular and extracellular stages
of the nairovirus replication cycle and that ablation of HSP70
activity using small-molecule inhibitors resulted in a 1,000-fold
reduction of infectious HAZV production. This suggests that
HSP70 family members perform an important role within the
nairovirus replication cycle and that inhibition of HSP70 function
may be an important therapeutic strategy for currently untreat-
able viral diseases.
MATERIALS AND METHODS
Mammalian cell culture. SW13 cells, which are of human adrenal cortex
carcinoma cell origin (25), were a kind gift from Stuart Dowall and Roger
Hewson of Public Health England (PHE). HEK293T cells, which are of
human embryonic kidney cell origin (26), and A549 cells, which are of
human alveolar carcinoma cell origin (27), were obtained from the Health
Protection Agency Culture Collections (HPACC). All cell lines were
maintained in Dulbecco’s modified Eagle’s medium (DMEM; Sigma-
Aldrich) supplemented with 10% fetal bovine serum (FBS; Invitrogen),
100 IU of penicillin/ml, and 100 g streptomycin/ml and incubated at
37°C in the presence of 5% CO2. To perform stable isotope labeling of
amino acids in cell culture (SILAC) differential cell labeling studies,
HEK293T cells were grown in SILAC DMEM supplemented with 10%
dialyzed FBS (Dundee Cell Products), 100 IU of penicillin/ml, and 100 g
streptomycin/ml. Media were named either “light” (R0K0) or “medium”
(R6K4), depending on the inclusion of stable isotopes of carbon (13C) or
hydrogen (2H) in arginine and lysine amino acids. Cells were grown in
these media for a minimum period of 2 weeks (7 cell divisions) prior to
transfection to ensure 95% cellular protein labeling. For both light-
medium- and medium-medium-labeled cells, four 10-cm2 dishes were
seeded with 1.25  106 HEK293T cells each 24 h prior to transfection.
Plasmids encoding nairovirus N proteins. The CCHFV N protein
cDNA sequence from strain Baghdad-12 was cloned into the pEGFP-C2
vector (Clontech) to allow mammalian cell expression of the CCHFV N
protein fused to the C terminus of enhanced green fluorescent protein
(EGFP), and the resulting plasmid (pEGFP-CCHFV-N) was verified by
sequencing. Expression of native CCHFV N was performed by cloning the
cDNA described above into pCAGGS to derive plasmid pCAGGS-
CCHFV-N. Expression of both the EGFP-N fusion protein (EGFP–
CCHFV-N) and the native CCHFV N protein was confirmed by immu-
nofluorescence (IF) and confocal microscopy as well as by Western blot
analysis using either an anti-EGFP antibody (Santa Cruz Biotechnology;
sc8334) or an anti-CCHFV N antibody generated in-house (described
below).
Bacterial cell expression of nairovirus N proteins and antibody pro-
duction. cDNAs comprising the open reading frames of the N protein of
CCHFV strain Baghdad-12 (GenBank accession number AJ538196.1) and
HAZV strain JC280 (GenBank accession number M86624.1) optimized
for bacterial expression were synthesized by Dundee Cell Products. Ex-
pression of CCHFV N and HAZV N in Escherichia coli was carried out as
described previously (Carter et al. [11]; Surtees et al. [14]). Following
purification, N purity was confirmed to be 95% by SDS-PAGE, and 1
mg N protein in a 1-ml volume was used for antibody production in sheep
by AltaBiosciences Ltd. (United Kingdom).
Transfection. HEK293T cells were transfected using Ca3(PO4)2 with
10 g plasmid DNA encoding EGFP–CCHFV-N or EGFP per 10-cm2
dish. For immunoprecipitation (IP), four 10-cm2 dishes were transfected.
Plasmid DNA was added to a solution containing sterile filtered 244 mM
CaCl2, which was added to sterile 2 HBS (274 mM NaCl, 302 M
Na2HPO4·12H2O, 55 mM HEPES [pH 7]). Solutions of CaCl2, DNA, and
2 HBS were incubated at room temperature for 30 min, prior to addi-
tion to HEK293T cells. Complete media containing transfection mixes
were incubated with HEK293T cells overnight, and then the media were
replaced with fresh media or cells were harvested. To visualize CCHFV N
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protein using indirect immunofluorescence microscopy, HUH-7 cells
were transfected in 60% to 70% confluent 12-well plates using 0.7 g
pCAGGS-CCHFV-N in 100 l Opti-MEM with 3 l Lipofectamine 2000
(Invitrogen).
Nairovirus infections. CCHFV (strain Baghdad-12) was used to in-
fect SW13 cells at a multiplicity of infection (MOI) of 1.0 under maximum
containment conditions at Public Health England, Porton Down, Salis-
bury, United Kingdom. At 24 h postinfection, cells were lysed and lysates
were used in IPs using protein G-coupled Dynabeads, as described below.
For HAZV purification, strain JC280 was propagated in SW13 cells at an
MOI of 0.001 under biosafety level 2 (BSL2) conditions. After 4 days, the
supernatant containing infectious HAZV was harvested and clarified by
centrifugation at 4,000  g at 4°C for 20 min. For HAZV N IPs, subcon-
fluent SW13 cells grown in 10-cm2 dishes were infected with HAZV at an
MOI of 1, and 24 h postinfection, cell lysates were used in HAZV N IPs as
described below.
HAZV purification. Clarified supernatant from HAZV-infected
SW13 cells was mixed with 50% (wt/vol) polyethylene glycol (PEG)
6000 –TNE buffer (0.01 M Tris [pH 7.4], 0.1 M NaCl, 1 mM EDTA) to
give a final PEG 6000 concentration of 10% (wt/vol). HAZV was precip-
itated overnight at 4°C and then recovered by centrifugation at 4,000  g
for 30 min at 4°C. The resulting pellet was resuspended in 1 ml of TNE
buffer and then layered on top of a continuous 5% to 25% iodixanol
gradient in a PolyClear centrifuge tube (Seton) (13 by 51 mm). After
ultracentrifugation at 250,000  g for 2.5 h at 4°C, HAZV particles were
isolated using a syringe, mixed gently, and frozen at 80°C.
Plaque assays. Plaque assays were performed in 12-well plates using
confluent SW13 cells. After adsorption, virus was removed and replaced
with media diluted 1:1 with 1.6% (wt/vol) high-viscosity carboxy-methyl
cellulose (Sigma-Aldrich). At 6 days, cells were fixed in 20% (vol/vol)
formalin for 1 h, washed 3 times in double-distilled water (ddH2O), and
then stained with crystal violet to visualize plaques.
Preparation of cell lysates. Cells were harvested from culture dishes
by scraping into media and then recovered by centrifugation at 4°C at
4,000  g for 5 min, washed 3 times in phosphate-buffered saline (PBS),
and then resuspended in lysis buffer (10 mM Tris-HCl [pH 7.5], 150 mM
NaCl, 0.5 mM EDTA, 0.5% NP-40, 1 EDTA-free complete protease
inhibitor; Roche) for IP or in radioimmunoprecipitation assay (RIPA)
buffer (50 mM Tris-HCl [pH 7.5], 150 mM NaCl, 1% [vol/vol] NP-40
alternative, 0.5% [wt/vol] sodium deoxycholate, 0.1% 1 EDTA-free
complete protease inhibitor cocktail) for Western blot analysis. Cell pel-
lets were incubated in RIPA buffer for 30 min on ice, and then lysates were
clarified by centrifugation at 13,000  g at 4°C for 10 min and the super-
natant was either used directly or stored at 20°C.
EGFP-N immunoprecipitations (GFP-trap). EGFP and EGFP–
CCHFV-N protein IP experiments were performed using a single-domain
anti-GFP antibody conjugated to agarose beads (GFP-trap; Chromotek).
IPs with similarly conjugated red fluorescent protein (RFP-trap) were
performed as nonbinding negative controls. Cell pellets were incubated
for 30 min with 200 l lysis buffer (10 mM Tris-HCl [pH 7.5], 150 mM
NaCl, 0.5 mM EDTA, 0.5% NP-40, 1 EDTA-free protease inhibitor
[Roche]). The lysate was clarified and diluted 5-fold with dilution buffer
(10 mM Tris-HCl [pH 7.5], 150 mM NaCl, 0.5 mM EDTA, 1 EDTA-free
protease inhibitor [Roche]). The GFP-trap/RFP-trap beads were incu-
bated with diluted cell lysate for 2 h at 4°C and then centrifuged at
2,700  g for 2 min followed by two washes with wash buffer (10 mM
Tris HCl [pH 7.5], 250 mM NaCl, 0.5 mM EDTA, 1 EDTA-free
protease inhibitor [Roche]) and then one wash with wash buffer con-
taining 275 mM NaCl. After centrifugation at 2,700  g, pelleted beads
were resuspended in 2 LDS-sample buffer (10 mM Tris-HCl [pH 7.5],
150 mM NaCl, 0.5 mM EDTA, 1 protease inhibitor cocktail, 1 LDS, 50
mM dithiothreitol [DTT]) and heated at 95°C for 10 min. Equal volumes
of labeled IP samples were mixed and analyzed by liquid chromatogra-
phy-tandem mass spectrometry (LC-MS/MS).
Native nairovirus N protein immunoprecipitation. Recombinant
protein G-coupled Dynabeads (Novex) were used to IP native nairovirus
N proteins from virus-infected and transfected cell lysates using the cor-
responding anti-N antibodies. Dynabead IPs were carried out using a
Dynabead protein G IP kit (Life Technologies) according to the manufac-
turer’s instructions. Briefly, 50 l Dynabeads was bound to CCHFV or
HAZV N antibodies and then incubated with infected or transfected cell
lysates for 15 min at room temperature. Antigen-antibody complexes
were washed in wash buffer, and proteins were eluted by heating at 95°C
for 10 min in 2 LDS buffer.
Immunofluorescence (IF). To visualize various proteins, cells were
grown on 19-mm-diameter glass coverslips housed in 12-well plates. After
infection or transfection, cells were washed twice in PBS prior to fixation
using either 4% formaldehyde (BHD Chemicals)–PBS for 10 min at room
temperature or 4% paraformaldehyde (PFA; BHD Chemicals) diluted in
PBS for 20 min at room temperature. After fixative removal, cells were
washed 3 times with PBS and then permeabilized in 0.5% (vol/vol) Triton
X-100 –PBS for 12 min at room temperature. Permeabilized cells were
washed 3 times in PBS and then blocked in 2% (vol/vol) FBS–PBS for 30
min. Primary and secondary antibody incubations were performed with
antibodies diluted to the appropriate concentration in 2% (vol/vol) FBS–
PBS; after blocking, cells were incubated with 50 l of the appropriate
primary antibody for 1 h at room temperature and then washed 3 times in
PBS and incubated with 50 l of the appropriate fluorescently labeled
secondary antibody for 1 h at room temperature. Cells were washed in
PBS prior to mounting onto glass slides using ProLong Gold antifade
reagent (Life Technologies) containing DAPI (4=,6-diamidino-2-phe-
nylindole). Slides harboring fixed and stained cells were analyzed by con-
focal microscopy using either an inverted laser scanning microscope
(LSM; 510 Meta Axiovert 200M) or an upright LSM (510 Meta Axioplan)
(Carl Zeiss Ltd.).
MS analysis of immunoprecipitated EGFP–CCHFV-N cell lysates.
Protein samples generated by GFP-trap IPs were analyzed by SDS-PAGE
and separated proteins isolated in 10 slices and subjected to in-gel diges-
tion with trypsin. The resulting peptides were separated using an Ultimate
U3000 nanoflow LC system (Dionex Corporation) consisting of a solvent
degasser, micro- and nanoflow pumps, a flow control module, a UV de-
tector, and a thermostated autosampler. A sample volume of 10 l (com-
prising 2 g) was loaded with a constant flow of 20 l/min onto a PepMap
C18 trap column (Dionex Corporation) (0.3 mm by 5 mm). After trap
enrichment, peptides were eluted onto a PepMap C18 nano column (Di-
onex Corporation) (75 m by 15 cm) with a linear gradient of 5% to 35%
solvent B (90% acetonitrile with 0.1% formic acid) over 65 min at a con-
stant flow rate of 300 nl/min. The high-performance LC (HPLC) system
was coupled to a LTQ Orbitrap XL system (Thermo Fisher Scientific Inc.)
via a nano electrospray (ES) ion source (Proxeon Biosystems). The spray
voltage was set to 1.2 kV, and the temperature of the heated capillary was
set to 200°C. Full-scan MS survey spectra (m/z 335 to 1,800) in profile
mode were acquired in the Orbitrap system with a resolution of 60,000
after accumulation of 500,000 ions. The five most intense peptide ions
with regard to detected abundances from the Orbitrap preview scan were
fragmented by collision-induced dissociation (normalized collision en-
ergy, 35%; activation Q, 0.250; activation time, 30 ms) in the LTQ Or-
bitrap XL system after accumulation of 10,000 ions. Maximal filling times
were 1,000 ms for the full scans and 150 ms for the MS/MS scans. Precur-
sor ion charge state screening was enabled, and all unassigned charge
states as well as singly charged species were rejected. The dynamic exclu-
sion list was restricted to a maximum of 500 entries, with a maximum
retention period of 90 s and a relative mass window of 10 ppm. The lock
mass option was enabled for survey scans to improve mass accuracy. The
data were acquired using Xcalibur software. LC-MS/MS analysis was per-
formed twice on the same protein sample.
Peptide quantification. Quantification was performed with Max-
Quant version 1.0.7.4 (28) based on the two-dimensional centroid of the
isotope clusters within each SILAC pair. The generation of values corre-
Functional Interaction between Nairovirus N and HSP70
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sponding to peak list, SILAC-based, and extracted ion current-based
quantitation, calculated posterior error probability, false-discovery rate
based on search engine results, peptide-to-protein group assembly, and
data filtration and presentation was carried out using MaxQuant. The
derived peak list was searched with the Mascot search engine (Matrix
Science, London, United Kingdom) against a concatenated database from
the International Protein Index (IPI) human protein database and the
reversed sequences of all proteins. Combined data sets from the two dif-
ferent experiments were deposited in the PRoteomics IDEntifications da-
tabase (PRIDE) using the PRIDE converter tool and are presented as an
annotated table (see Data set S1 in the supplemental material).
Western blot analysis. Proteins were resolved on 12% SDS polyacryl-
amide gels and transferred to polyvinylidene difluoride (PVDF) mem-
branes (Immobilon-P; Millipore) or fluorescence-compatible PVDF
membranes (FL-PVDF) (Immobilon-FL Transfer membranes; Millipore)
using a Trans-Blot semidry cell (Bio-Rad) in Towbin buffer (25 mM Tris,
192 mM glycine, 20% [vol/vol] methanol) for 1 h at 15 V. Membranes
were blocked for 1 h at room temperature in 10% (wt/vol) bovine serum
albumin (BSA) (Sigma-Aldrich)–Tris-buffered saline (TBS) supple-
mented with 0.01% Tween 20 (TBS-T) (50 mM Tris-HCl [pH 7.5], 150
mM NaCl, 0.1% Tween 20). FL-PVDF membranes were blocked for 1 h at
room temperature in 50% (vol/vol) Odyssey blocking buffer (LiCor)–TBS
(50 mM Tris-HCl [pH 7.5], 150 mM NaCl). Membranes were incubated
with primary antibody diluted appropriately in 5% (wt/vol) BSA–1
TSB-T or in 50% Odyssey blocking buffer–TBS either for 1 h at room
temperature or at 4°C overnight. Primary antibodies used include those
raised against GFP (Santa Cruz Biotechnology; sc-8334), HSP70/HSC70
(Abcam; Ab6535), vimentin (Santa Cruz Biotechnology; sc-966), actin
(Sigma-Aldrich; A3853), B23.1 (Santa Cruz Biotechnology; sc47725), p53
(Cell Signaling; 9282), and GAPDH (glyceraldehyde-3-phosphate dehy-
drogenase) (Abcam; ab8245). PVDF membranes were incubated with an
appropriate secondary antibody conjugated to horseradish peroxidase
(HRP) as described above. FL-PVDF membranes were similarly processed
but were incubated with the appropriate fluorescently labeled secondary
antibody. PVDF membranes were washed in TBS-T and once in water,
and proteins were visualized using enhanced chemiluminescence on pho-
tographic film. FL-PVDF membranes were washed in TBS and once in
water and then imaged using a LiCor Odyssey Sa system (LiCor).
MS analysis of purified virus; sample preparation and tryptic diges-
tion. Purified virus comprising approximately 11 g protein was dena-
tured by heating for 10 min at 95°C in the presence of DTT. Viral proteins
and controls were run approximately 1 cm into a 4% to 12% Tris-Bis
gradient gel, and the proteins were visualized using Coomassie staining.
The entire gel lane was excised and cut into smaller pieces, destained in
50% acetonitrile–50 mM ammonium bicarbonate (pH 8), reduced for
30 min at 37°C with 10 mM dithiothreitol (Sigma-Aldrich)–50 mM am-
monium bicarbonate, and alkylated with 55 mM iodoacetamide
(Sigma)–50 mM ammonium bicarbonate for 30 min at room tempera-
ture. Gel pieces were washed for 15 min in 50 mM ammonium bicarbon-
ate and dehydrated with 100% acetonitrile. Acetonitrile was removed, and
the gel plugs were rehydrated with 0.01 g/l proteomics-grade trypsin
(Sigma-Aldrich) in 50 mM ammonium bicarbonate. Digestion was per-
formed overnight at 37°C. Peptides were extracted from the gel plugs
using successive 15-min incubations and 3% (vol/vol) acetonitrile– 0.1%
(vol/vol) trifluoroacetic acid (TFA). Peptide extracts were pooled and
reduced to dryness using a centrifugal evaporator (Microfuge concentra-
tor plus) and resuspended in 3% (vol/vol) acetonitrile– 0.1% (vol/vol)
TFA for analysis by mass spectrometry.
Mass spectrometry of purified HAZV proteins. Peptide mixtures (2
l) were analyzed by on-line nanoflow liquid chromatography using an
nanoACQUITY-nLC system (Waters MS Technologies) coupled to an
LTQ-Orbitrap Velos (Thermo Fisher Scientific) mass spectrometer
equipped with a nanospray ion source. The analytical column (nano-
ACQUITY ultraperformance LC [UPLC] BEH130 C18) (15 cm by 75 m,
1.7 m capillary column) was maintained at 35°C with a flow rate of 300
nl/min. The gradient consisted of 3% to 40% acetonitrile– 0.1% formic
acid for 150 min followed by a ramp of 40% to 85% acetonitrile– 0.1%
formic acid for 5 min. Full-scan MS spectra (m/z range, 300 to 2,000) were
acquired by the Orbitrap at a resolution of 30,000. The top 20 most intense
ions from the MS1 scan (full MS) were selected for tandem MS by colli-
sion-induced dissociation, and all product spectra were acquired in the
LTQ ion trap. Spectral data were transformed to .mgf files with Proteowiz-
ard (version 3.0) (29) and used for peptide identification performed with
the Mascot (version 2.3.02; Matrix Science) search engine. Tandem MS
data were searched against the predicted HAZV and human proteomes
(UniProt release 2014_02). Mascot search parameters were as follows:
precursor mass tolerance set to 10 ppm and fragment mass tolerance set to
0.8 Da. A maximum of one missed tryptic cleavage was permitted. Carb-
amidomethylation (cysteine) was set as a fixed modification and oxida-
tion (methionine) as a variable modification. Mascot search results were
further processed using Percolator. The false-discovery rate was 1%.
Individual ion scores of 13 indicated identity or extensive homology
(P  0.05). Approximate label-free spectrum-counting-based quantita-
tion of the proteins was determined using the exponentially modified
protein abundance index (emPAI) calculated automatically by the Mascot
search engine (30).
HSP70/HSC70 inhibition. Small-molecule inhibitors VER155008
(VER) and pifithrin- (PIF) (Sigma-Aldrich) were both dissolved in di-
methyl sulfoxide (DMSO) (Sigma-Aldrich) to make 10 mM stocks, which
were further diluted in DMEM supplemented with 2% FBS to the appro-
priate working concentrations. Assay results were compared to those ob-
tained with DMEM supplemented with 2% FBS containing 0.4% DMSO.
A549 cells were seeded in 12-well plates such that the cells were 60% to
70% confluent when infected and were then exposed to the appropriate
concentration of PIF and VER. After 1 h, cells were infected with HAZV at
an MOI of 1 and subsequently replaced with fresh media containing ap-
propriate concentrations of PIF and VER. At 24 h postinfection, cell cul-
ture supernatants and whole-cell lysates were harvested and plaque as-
sayed or analyzed by Western blotting.
RESULTS
Expression of the EGFP–CCHFV N fusion protein. To identify
cellular proteins that interacted with the nairovirus N protein dur-
ing the replication cycle, an IP-based strategy was used to isolate
the CCHFV N protein from cells in culture followed by mass spec-
trometry (MS) to identify coprecipitating cellular proteins.
CCHFV N was initially expressed as an EGFP fusion protein
(EGFP–CCHFV-N) in HEK293T cells, chosen for three principal
reasons: first, their proven ability to support CCHFV replication;
second, the availability of annotated human proteome databases
to facilitate protein identification and function assignment; and
third, their ability to be efficiently transfected using calcium phos-
phate. Western blot analysis of pEGFP-CCHFV-N-C2-trans-
fected cells identified a protein with the expected 87-kDa molec-
ular mass predicted for EGFP–CCHFV-N (Fig. 1A). Direct
immunofluorescence (IF) confocal analysis of EGFP–CCHFV-N-
expressing HEK293T cells identified fluorescence in perinuclear
regions and also in discrete puncta elsewhere in the cytoplasm
(Fig. 1B), a distribution that has been previously described for N
during CCHFV infection (23, 31, 32) (see also Fig. 3C). This dis-
tribution contrasts with the localization of EGFP alone, expressed
from pEGFP-C2, which was detected diffusely throughout both
the cytoplasm and nucleus (Fig. 1B).
Immunoprecipitation of EGFP–CCHFV-N. To identify cellu-
lar proteins that interacted only with the N moiety of the EGFP–
CCHFV-N fusion protein, the precipitated proteins from two dif-
ferent cell populations, one expressing EGFP–CCHFV-N and the
other expressing EGFP alone, were compared. Comparison of the
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resulting data sets facilitated the elimination of likely nonspecific
interaction partners and guided further experimentation to iden-
tify proteins specifically binding to CCHFV N.
EGFP–CCHFV-N and EGFP were isolated from separate cul-
tures of HEK293T cells by IP using a protocol involving a so-called
GFP-trap, which comprises a single-chain anti-EGFP monoclonal
antibody conjugated to agarose. Clarified cell lysates were incu-
bated with the GFP-trap to allow EGFP or EGFP–CCHFV N to
bind, along with the associated cellular proteins, and then bound
proteins were examined by SDS-PAGE followed by either Coo-
massie staining (Fig. 1C) or Western blotting (Fig. 1D) using an
anti-EGFP and/or anti-CCHFV N antibody. Equal volumes of
each eluate were mixed together, and combined IP samples were
analyzed by mass spectrometry (MS).
To quantify subsequently detected CCHFV N binding proteins,
stable isotope labeling by amino acids in cell culture (SILAC) was
used in which the entire cellular proteome was metabolically labeled
by incorporation of amino acids containing stable isotopes. Cells ex-
pressing EGFP were grown using medium media (containing isoto-
pically labeled arginine and lysine), whereas cells expressing EGFP–
CCHFV-N were grown in light media (without labeled amino acids).
After the IP samples were mixed, distinct masses of precipitated pep-
tides were resolved by MS, which revealed the identities and quanti-
ties of proteins associated with EGFP–CCHFV-N and of those asso-
ciated with EGFP, allowing the relative protein quantities to be
represented as a fold abundance difference value. Cell proteins asso-
ciated with CCHFV-N would be expected to be highly abundant in
the EGFP–CCHFV-N precipitated fraction and to be in low abun-
dance (or absent) in the EGFP precipitated fraction and so would give
a correspondingly high abundance ratio.
Identification of cellular proteins that interact with the
CCHFV N protein. In order to provide increased confidence in
our data sets, the LC-MS/MS analysis of cellular proteins that
coprecipitated with EGFP–CCHFV N and EGFP was carried out
twice. A total of 192 proteins were identified, with 112 common to
both analyses, 46 proteins unique to the first analysis, and 34
unique to the second analysis, and all these are listed in Data set S1
in the supplemental material.
Previous studies have suggested that the majority of proteins
identified by MS in SILAC-based GFP-trap experiments represent
proteins that bind nonspecifically to EGFP or to the GFP-trap
agarose matrix (33, 34). However, the ratio of the abundance of
cellular proteins precipitated with EGFP–CCHFV-N to the abun-
dance of those precipitated with EGFP can guide interaction spec-
ificity, and previous studies suggest that a ratio of 5 represents a
conservative threshold under which interactions are likely non-
specific (34). A rational assessment of all identified proteins was
performed in order to generate a priority listing of putative inter-
actors; the basis for this selection process was a combination of the
calculated EGFP–CCHFV-N/EGFP abundance ratio (approxi-
mately 5 or greater in both analyses) and a high significance value,
calculated from the unique peptide counts and their correspond-
ing abundances. The resulting 6 most likely authentic interacting
proteins are listed in Fig. 2. As described above, the CCHFV N
protein has previously been shown to bind actin (23), and so this
known interaction represented an opportunity to assess the suc-
cess of the GFP-trap and MS/MS identification procedure. In
good agreement with this work, cytoplasmic actin was identified
in both LC-MS/MS analyses by detection of 19 and 17 peptides
with increased ratios of 6.8-fold and 16.5-fold, respectively.
Independent validation of interacting partners by Western
blot analysis. As described above, a list of cellular proteins that
potentially interacted with CCHFV N was derived from the MS
analysis of IPs using EGFP–CCHFV-N protein. Next, IPs were
repeated using unlabeled HEK293T cell lysates expressing either
EGFP–CCHFV-N or native EGFP, in order to verify the putative
protein-protein interactions. To determine if cell proteins were
precipitated due to nonspecific interactions with components of
the GFP-trap, control IPs were performed using both uncoupled
agarose beads and a non-cross-reacting red fluorescent protein
trap (RFP-trap) in which antibodies specific for RFP replaced
those specific for GFP. As expected, Western blot analysis showed
that the GFP-trap specifically immunoprecipitated EGFP–
CCHFV-N and EGFP, whereas the RFP-trap and the agarose bead
controls did not (Fig. 2, row 1), thus confirming the effectiveness
of the GFP-trap for specific precipitation of EGFP and EGFP–
CCHFV-N.
The nonlabeled IPs were probed by Western blotting using
FIG 1 Expression and immunoprecipitation of EGFP–CCHFV-N in HEK293T cells. (A) HEK293T cells were transfected with a plasmid designed to express an
EGFP–CCHFV-N fusion protein, which was detected by Western blot analysis of cell lysates using an anti-CCHFV N antibody. M, molecular mass marker lane
(values at the left are in kilodaltons). (B) HEK293T cells were transfected with plasmids expressing EGFP or EGFP–CCHFV-N, and their subcellular localization
was determined using confocal microscopy, with the nucleus stained blue using DAPI and with EGFP and EGFP–CCHFV-N detected as green. (C and D)
Following GFP-trap-mediated IP from EGFP- and EGFP–CCHFV-N-expressing cells, proteins were resolved by SDS-PAGE and visualized by either Coomassie
staining (C) or Western blotting (D) with an anti-GFP antibody. Unfilled arrowheads denote EGFP–CCHFV-N.
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antibodies against selected cellular proteins identified by the LC-
MS/MS analysis. As described above, cellular actin is known to
bind CCHFV N protein (23), and so this known interaction was
again used as a positive control. In agreement with the previous
work, Western blot analysis of IPs using EGFP–CCHFV-N-
transfected cell lysates revealed that actin was abundantly co-
immunoprecipitated using the GFP-trap but that no actin was
detected following IPs using the control RFP-trap or agarose
beads alone (Fig. 2, row 2). Other cellular components that
exhibited high EGFP–CCHFV-N/EGFP binding ratios and
were identified by multiple peptides included heat shock pro-
tein 70 (HSP70), heat shock cognate 71-kDa protein (HSC70),
vimentin, the p53 tumor suppressor protein, and tubulin. For
each of these cellular proteins, Western blot analysis of IPs
from EGFP–CCHFV-N-expressing cells detected a corre-
sponding protein of the appropriate molecular mass both in
the input material and following IP using the GFP-trap, with
no binding or much reduced binding to either the agarose
beads alone or the RFP-trap (Fig. 2, rows 3 to 6). None of these
chosen cellular proteins were identified in similar quantities in
GFP-trap IPs from cells expressing EGFP alone, indicating that
the interaction between these cellular proteins is EGFP–
CCHFV-N specific.
GAPDH and nucleophosmin (B23.1/NPM1) were identified in
the LC-MS/MS analysis as having low abundance ratios in EGFP–
CCHFV-N/EGFP IPs of 4 and 4.5, respectively, indicative of likely
nonspecific interactions (34). In agreement with this, our Western
blot analysis failed to detect the presence of either of these proteins
in the IPs from the GFP trap when EGFP–CCHFV-N was ex-
pressed in cells (Fig. 2, rows 7 and 8). In addition, -tubulin also
exhibited similarly low ratios of 5.1 and 5.5 in the two LC-MS/MS
analyses. Consistent with this, subsequent Western blot analysis
detected -tubulin in the GFP-trap IPs from EGFP–CCHFV-N-
transfected cells with much reduced intensity compared to input
cell lysate, suggesting that -tubulin may represent a weak or tran-
sient interacting protein.
Validation of the HSP70-N interaction using native CCHFV
N. The results described in the previous section identified cellular
proteins that interacted with the EGFP CCHFV N fusion protein,
including HSP70 and HSC70, which are members of a group of
related proteins that form the HSP70 family of cellular chaperones
(35). Functional interactions between heat shock proteins and
viral components have recently been documented in other RNA
viruses, and so we further pursued this potential interaction. In
order to exclude the possibility that the association between
HSP70 and N was influenced by the EGFP moiety, native CCHFV
N protein was expressed both transiently in HEK293T cells and
during authentic CCHFV infection, followed by its precipitation
with anti-CCHFV N antibodies made in-house. The specificity of
these antisera was confirmed by Western blot analysis using ma-
terial harvested from HEK293T cells transfected with a CCHFV N
expression plasmid as well as lysates from CCHFV-infected SW13
cells. In both cases, the CCHFV N antisera detected a single band
of the expected 54-kDa molecular mass (Fig. 3A and C, top rows,
Input). The subcellular distributions of native CCHFV N ex-
pressed either transiently (Fig. 3B) or in CCHFV-infected SW13
cells (Fig. 3D) were indistinguishable, being predominantly peri-
nuclear, with additional puncta containing CCHFV N detected in
the cytoplasm.
IP of native CCHFV N from both infected and transfected cells
was achieved using Dynabeads conjugated to anti-CCHFV N an-
tibodies, after which precipitated proteins were analyzed by West-
ern blotting. The effectiveness of the IP procedure was confirmed
by the detection of abundant CCHFV N protein in IP samples
(Fig. 3A and C, top rows, anti-CCHFV N) and the absence of
CCHFV N in the lanes corresponding to mock-transfected or
mock-infected cell lysates (Fig. 3A and B, top row, Mock anti-N)
and unconjugated antibodies incubated with transfected or in-
fected cell lysates (Fig. 3A and B, top row, N unbound). The IP
samples were analyzed by Western blotting using an anti-HSP70
antibody, which revealed the abundant presence of a correspond-
ing 70-kDa protein in the anti-CCHFV N IP samples from tran-
FIG 2 Validation of selected CCHFV N protein cellular interaction partners. HEK293T cells were transfected with EGFP–CCHFV-N and EGFP, and, 24 h later,
cell lysate components were immunoprecipitated with GFP-trap, RFP-trap, or unconjugated agarose beads. The resulting IPs were separated by PAGE and then
subjected to Western blotting to probe for the presence of the selected cellular proteins listed using specific antibodies. The ratios of the abundances of these
proteins determined by the two SILAC LC-MS/MS analyses are indicated, and a complete list of all interaction partners is provided as an annotated table in Data
set S1 in the supplemental material.
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siently transfected cells, with no or little protein detected in mock-
transfected cells (Fig. 3A, boxed lanes). Similarly, anti-HSP70
Western blot analysis of N protein precipitated from CCHFV-
infected cells identified a 70-kDa protein, with little or no corre-
sponding protein detected in mock-infected cells (Fig. 3B, boxed
lanes). The two cellular proteins that were not considered to be
CCHFV N interacting partners, GAPDH and B23.1 (nucleophos-
min), were chosen to act as negative controls. Consistent with the
proteomics analysis, neither of these cellular proteins was detected
by Western blotting in the anti-CCHFV N IP samples.
To further examine the interaction between CCHFV N and
HSP70/HSC70, indirect IF confocal microscopy was performed to
determine the cellular localization of endogenous HSP70 and na-
tive CCHFV N transiently expressed in SW13 cells. This analysis
showed that HSP70/HSC70 was present at multiple discrete loca-
tions throughout the cell, with staining present predominantly
within the cytoplasm, and often with dense staining in perinuclear
regions of both transfected and untransfected cells (Fig. 3E).
Costaining of cells with CCHFV N antisera revealed a predomi-
nantly perinuclear distribution, and, in many instances, the
CCHFV N-positive puncta colocalized with HSP70/HSC70. This
suggested that a subset of HSP70/HSC70 molecules were associ-
ated with CCHFV N, although abundant unassociated HSP70/
HSC70 was also detected within infected cells, which was expected
due to its native chaperone roles.
HAZV N protein interacts with HSP70 inside infected cells.
The results described in the previous section demonstrated that
HSP70 interacted with CCHFV N in infected cells. To determine
whether this interaction was a common feature of nairovirus N
proteins, this interaction was also investigated using HAZV N,
exploiting the significant logistical advantages of working under
BSL2 conditions rather than under the highly restrictive maxi-
mum containment conditions required for CCHFV.
SW13 cells were infected with HAZV at an MOI of 1, and N
protein was precipitated 24 h after infection by the use of anti-
HAZV N antisera under the same conditions used to IP native
CCHFV N. The ability of the anti-HAZV N antiserum to detect
HAZV N was confirmed by Western blot analysis of cell lysates
infected with HAZV, which detected a band of the appropriate
molecular mass (54 kDa); HAZV N was detected in the input and
the anti-HAZV N IP lanes but was absent from the negative-con-
trol lanes. Next, the co-IP of HSP70/HSC70 with HAZV N was
confirmed by Western blot analysis of IP samples using an anti-
HSP70 antibody. This specifically identified a 70-kDa protein in
the input sample and also in the anti-HAZV N IP sample (Fig. 4A),
thus identifying HSP70/HSC70 as an HAZV N interaction partner
within infected cells. HSP70/HSC70 was not detected or was de-
tected to a much lesser extent in the IP control lanes from mock-
infected cells or in precipitations performed using the unconju-
gated Dynabead matrix.
To further evaluate the interaction between N and HSP70 dur-
ing nairovirus infection, indirect IF confocal microscopy was used
to determine the subcellular localization of both N and HSP70/
HSC70 during HAZV infection. As described above for CCHFV
N, indirect IF analysis showed that HSP70/HSC70 partially colo-
calized with HAZV N in sites that were predominantly perinu-
clear, but staining of HSP70/HSC70 in sites that were free of
HAZV N was also evident (Fig. 4B). Taken together, the results
suggest that a subset of HSP70/HSC70 molecules are associated
with HAZV N during infection but that free HSP70/HSC70 also
exists within infected cells, presumably performing its native
chaperone function with other client proteins.
FIG 3 Interaction between cellular HSP70 and native CCHFV N expressed transiently or during CCHFV infection. (A) Anti-CCHFV N antisera was used for IP
of native CCHFV N expressed in HEK293T cells, and the isolated proteins were analyzed by Western blotting using the antibodies shown. (B) The subcellular
localization of native CCHFV N in HUH-7 cells was investigated using indirect immunofluorescence microscopy using anti-CCHFV N antisera, shown as green.
Nuclei are stained with DAPI, shown as blue. (C) Anti-CCHFV N antisera was used for IP of native CCHFV N from CCHFV-infected SW13 cells, and the isolated
proteins were analyzed by Western blotting using the antibodies shown. (D) The subcellular localization of native CCHFV N in CCHFV-infected SW13 cells was
investigated by indirect immune fluorescence microscopy using anti-CCHFV N antisera, shown as green. The nuclei are stained with DAPI, shown as blue. (E)
Indirect confocal immunofluorescence analysis of SW13 cells transiently expressing native CCHFV-N protein expressed from a plasmid cDNA. Cells were
costained using antibodies specific for CCHFV N (green) and anti-HSP70 (red), with donkey and chicken secondary antibodies, respectively, as well as DAPI
(blue).
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Identification of host cell proteins packaged within nairovi-
rus particles. The experiments described above showed that the
nairovirus N protein interacts with members of the HSP70 family
within virus-infected cells. One hypothesis that follows from this
is that HSP70 influences the conformation of RNPs during their
assembly into progeny virions, which would predict that the chap-
erone would be present within assembled and budded virus. To
test this, the composition of infectious nairovirus particles that are
released from cells was investigated. As maximum containment
protocols are required to grow and purify CCHFV, which is prob-
lematical, HAZV was used for this analysis instead. HAZV re-
leased from cells was purified by ultracentrifugation on an iodix-
anol gradient, resulting in a narrow opalescent band that was
aspirated (fraction VF1), with the remaining contents of the gra-
dient being collected as 4 sequential fractions (F2 to F5). All five
fractions were analyzed by SDS-PAGE followed by Coomassie
staining (Fig. 5A) or silver staining (Fig. 5B), which showed a
sharp peak in protein abundance in the initially aspirated VF1
fraction (the protein corresponding to the molecular mass of N
[shown by an asterisk]). Higher-molecular-mass proteins were
visible which may correspond to virus components Gn/Gc and L,
as well as proteins that were likely cellular in origin (Fig. 5A and
B). All fractions were analyzed for the presence of HAZV N pro-
tein by Western blotting using anti-HAZV N antibody (Fig. 5C,
top row), which revealed that HAZV N protein was almost exclu-
sively found in fraction VF1. Further confirmation that VF1 con-
tained purified HAZV was that only VF1 was demonstrated to
possess infectious virus by plaque assay, having a titer of 2  105
PFU/ml.
In order to elucidate the protein composition of purified infec-
tious HAZV, fraction VF1 was denatured and separated by SDS-
PAGE and proteins were identified by MS. In addition, the con-
tent of fraction F3 was also analyzed by MS to identify proteins
present throughout the gradient as background contaminants. A
total of 264 proteins were identified in VF1, and 82 proteins were
identified in F3 (see Data Set S2 in the supplemental material). Of
these 82 proteins, 69 were also identified in VF1. Unless the abun-
dances of these proteins were considerably increased within VF1,
they were likely dispersed throughout the gradient rather than
being associated within intact HAZV particles and thus could be
discounted from further analysis. The peptides identified in frac-
tions VF1 and F3 were ranked in accordance with their calculated
exponentially modified protein abundance index (emPAI) score.
As expected, the HAZV N, Gn, Gc, and L proteins were detected in
VF1, as was actin, previously reported to interact with the nairo-
virus N protein within cells (23). In contrast, analysis of fraction
F3 showed that actin and all HAZV proteins were either absent or
present in negligible quantities.
FIG 4 Analysis of the interaction between HAZV N and HSP70 in cells. (A) HAZV N was immunoprecipitated from HAZV-infected cells using anti-N antisera
and then subjected to Western blotting using the antibodies shown. (B) Indirect confocal immunofluorescence analysis of SW13 cells infected with HAZV
revealed HAZV N (green) localized in discrete cytoplasmic puncta, similarly to CCHFV N. HSP70 (red) was present in both the cytoplasm and nucleus and also
colocalized with HAZV N in some cytoplasmic puncta. Nuclei are stained with DAPI, shown as blue. Bottom row shows mock-infected cells.
FIG 5 SDS-PAGE analysis of purified HAZV harvested from SW13 cell supernatant and Western blot confirmation of the presence of HSP70 and HSP90 family
members. (A and B) Secreted HAZV particles harvested from infected SW13 cell supernatants were purified by PEG precipitation followed by centrifugation
through an iodixanol gradient. HAZV particles were isolated (lane VF1), and the remaining 4 fractions (1 ml each) were collected from the top of the gradient
(Fraction 2) to the bottom of the gradient (Fraction 5). Fractions were analyzed by SDS-PAGE and either Coomassie stained (A) or silver stained (B). (C) Fraction
VF1 was subjected to Western blot analysis using both anti-HAZV N antisera and antibodies targeting the listed cellular proteins, including HSP70. (D) HAZV
N was immunoprecipitated from purified infectious HAZV and then subjected to Western blot analysis using anti-HAZV N and anti-HSP70 antibodies.
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The MS analysis of VF1 identified peptides corresponding to
several members of the HSP70 family and also to members of the
HSP90 family. These findings were validated by performing West-
ern blot analysis on VF1, using antibodies specific for HSP70 and
HSP90 family members, which revealed the abundant presence of
proteins corresponding to HSP70/HSC70 and HSP90-alpha and
HSP90-beta (Fig. 5C). Trace quantities of these chaperones were
also detected in other fractions but in vastly reduced abundance
compared to VF1, consistent with their being highly enriched in
purified virus particles.
HSP70/HSC70 associated with HAZV N protein in infectious
particles. The findings described in the previous section indicated
the abundant presence of cellular chaperones of the HSP70 family
within purified HAZV particles. Next, we investigated whether
these chaperones were present within the HAZV particles in asso-
ciation with HAZV N by subjecting VF1 to IP using anti-HAZV N
antisera. The subsequently precipitated proteins were separated
by SDS-PAGE and then probed by Western blot analysis using
anti-HSP70 antibodies, which detected a 70-kDa protein consis-
tent with the HSP70/HSC70 targets. The lack of a similar identi-
fied protein in the control lanes from IPs performed using the
unconjugated Dynabead matrix or from F3 confirmed the speci-
ficity of this interaction (Fig. 5D). Taken together, these results
suggest that incorporation of HSP70/HSC70 in infectious HAZV
particles was mediated through specific interaction with N, most
likely in the form of RNPs.
Inhibition of HSP70 function using small-molecule inhibi-
tors. To further examine the importance of HSP70 family chap-
erones during the nairovirus replication cycle, the effects on
HAZV replication of two previously characterized HSP70 inhibi-
tors, pifithrin- (PIF) and VER155008 (VER), were evaluated.
HSP70 and its homologs comprise two functionally distinct do-
mains, namely, an N-terminal substrate-binding domain (SBD)
and a C-terminal ATPase domain that allosterically modulates the
activity of the SBD (35). PIF directly interacts with the SBD, thus
interfering with its ability to bind to client proteins, whereas VER
targets the ATPase domain, preventing ATP from binding and
consequently inhibiting HSP70 function by preventing allosteric
regulation of the SBD.
As described above, HAZV was utilized for this study due to
the relative ease of handling HAZV compared to CCHFV. In
order to assess the effects of VER and PIF on HAZV multipli-
cation, we first established their cytotoxicity profiles in A549 cells
by MTT [3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2Htetrazo-
lium bromide] assay (Fig. 6A) in comparison to a baseline of 0.4%
DMSO, which exceeded the maximal concentration of the solvent
used to deliver the compounds. Based on previous analyses of
HSP70 inhibition by our group (36), inhibitor concentrations of
between 5 and 20 M were tested, which resulted in no detectable
cellular toxicity and no reduction in GAPDH expression. We next
tested the ability of VER and PIF at 5, 10, and 20 M concentra-
tions to interfere with virus replication, as determined by plaque
assay. As the plaque assay measures the yield of secreted infectious
virus, it would determine how PIF and VER influence all intracel-
lular stages of the virus replication cycle as well as the ability of
released virus to infect new cells.
Incubation of HAZV-infected A549 cells with 20 M VER for
24 h reduced HAZV titers by approximately 1,000-fold compared
to the DMSO control results, whereas over the same 24-h period,
incubation with 20 M PIF reduced virus titers by approximately
500-fold (Fig. 6B). This indicated that the production of infectious
HAZV virions was greatly diminished in the presence of these
FIG 6 The effect of HSP70/HSC70 inhibitors VER and PIF on HAZV replication. (A) Cytotoxicity of VER and PIF in SW13 cells was assessed by MTT assay after
24 h of incubation of SW13 cells with VER and PIF at several different concentrations in the absence of HAZV. Cytotoxicity levels are presented relative to 0.4%
DMSO results. (B) The effect on HAZV replication of treating A549 cells with VER and PIF was determined by plaque assay, which revealed a reduction in HAZV
titers at subcytotoxic PIF and VER concentrations. The statistical significance of decreased virus multiplication using PIF and VER in relation to DMSO-only
controls was assessed using paired Student’s t tests, and significance is shown with an asterisk (* [P  0.05]). (C) Western blot analysis of HAZV N protein and
GAPDH levels within infected cells following PIF and VER treatment at subcytotoxic concentrations. (D) HAZV N protein levels quantified from Western blot
analyses performed in three experiments.
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compounds. These findings establish HSP70/HSC70 as having a
critical role in the nairovirus replication cycle.
To better understand this role, we next wanted to gain infor-
mation on the specific stage of the virus replication cycle at which
HSP70 and HSC70 acted. To achieve this aim, we examined the
effect of PIF and VER on the quantity of HAZV N protein that was
expressed during infection (Fig. 6C and D). This analysis revealed
a gradual decrease in HAZV N expression as the concentration of
VER increased, such that N expression was approximately 70%
that of the DMSO control at a subtoxic VER concentration of 20
M. When cells were incubated with PIF, the use of the same
subtoxic 20 M concentration resulted in a greater decrease in N
expression levels to approximately 25% of that seen with the
DMSO controls (Fig. 6C and D). These findings suggest that
HSP70/HSC70 is required during the HAZV replication cycle at a
stage prior to protein synthesis, such as genome replication or
gene expression, rather than at a later stage, such as virus assembly
and egress.
DISCUSSION
RNA viruses have limited coding capacity; to compensate for this,
many of their proteins exhibit remarkable structural economy,
often possessing multiple functions. An additional strategy that
viruses have adopted to increase their functional repertoire is that
of subverting the function of host cell components. Based on the
hypothesis that nairovirus N proteins must interact with specific
host cell proteins to complete the infectious cycle, we aimed to
determine the identity of these associating cellular factors. To
achieve this aim, we utilized both quantitative proteomics and
conventional IP protocols to elucidate the identity of interacting
cellular proteins that coprecipitate with CCHFV and HAZV N
proteins during both the intracellular and extracellular phases of
their replication cycles.
Our results indicated that many interacting proteins of
CCHFV N were components of the cellular cytoskeleton, includ-
ing actin, tubulin, and vimentin. Relevant to the current study,
CCHFV N has previously been shown to interact with actin, and
this provides further confidence in our findings. The role of these
cytoskeletal components in the CCHFV replication cycle is un-
clear, although strong possibilities must include the trafficking of
viral components from the site of virus entry or uncoating to the
virus factories where synthesis of viral components for later as-
sembly of progeny virions takes place. However, the most abun-
dant interacting partners of CCHFV N were members of the
HSP70 family of ATP-dependent cellular chaperones, which, in
association with DnaJ cofactor adapter proteins, perform roles
that relate to correct folding and transport of newly synthesized
and misfolded proteins, as well as to the assembly of multicompo-
nent complexes (37). We also showed that the N protein of the
closely related HAZV also associates with HSP70 family members,
not only within infected cells, but also in secreted infectious virus
particles. Due to the extremely close structural similarities of these
two N proteins (14), we suggest that the N-HSP70 interactions
that we have observed in both HAZV and CCHFV are similarly
related. This reasoning led us to test the functional role of HSP70
family members throughout the HAZV replication cycle and to
propose that the findings of this analysis would also apply to the
infectious cycle of CCHFV.
Growing evidence from the literature indicates that members
of the HSP70 family of chaperones functionally interact with pro-
teins belonging to viruses classified in many different groups span-
ning the DNA and RNA viruses infecting a bewildering array of
unicellular and multicellular organisms. For negative-stranded
RNA viruses (of which nairoviruses are examples), the most com-
monly reported role of HSP70/HSC70 is its interaction with com-
ponents of the viral RNA synthesis machinery, which influences
both transcription and replication of viral RNA. Examples include
HSP70/HSC70 interactions with the N proteins of rabies virus
(38), measles virus (39), and Hantaan virus (40), polymerase sub-
units PB1 and PB2 from influenza A virus (FLUAV) (41, 42), and
components of the human respiratory syncytial virus (HRSV)
polymerase complex (36, 43–45). Interestingly, the role of HSP70/
HSC70 in RNA synthetic processes has been shown to be some-
times stimulatory and sometimes inhibitory. In the case of HRSV,
depletion or inhibition of the associated heat shock proteins was
found to have an inhibitory effect on RNA synthesis, suggesting
that HSP70/HSC70 had a positive role in the viral replication cy-
cle, and it was postulated that the chaperone enhanced polymerase
activity by facilitating its correct folding. In contrast, the role of
HSP70 in FLUAV RNA synthesis is apparently more complex,
with initial reports suggesting that it disrupts polymerase-RNA
binding, leading to reduced transcription and replication (41).
However, more-recent conflicting reports indicate that FLUAV
RNA synthesis is stimulated by physiological concentrations of
HSP70 but inhibited when HSP70 is overexpressed through heat
shock stimulation or transient expression (42).
In order to assess whether the HSP70/HSC70 interaction was
beneficial or detrimental to the nairovirus replication cycle, we
tested the impact on HAZV replication of modulating HSP70/
HSC70 function using the previously described HSP70/HSC70
inhibitors PIF and VER (46). These chaperones, along with their
cofactors, are emerging as potent and promising antiviral targets
(47). PIF and VER were carefully titrated to ensure that the con-
centrations used were noncytotoxic as measured by MTT assay
and expression of cellular GAPDH. For both inhibitors, the yield
in secreted infectious virus was dramatically reduced by at least
90% when used at 20 M, a concentration which was conserva-
tively chosen to rule out any off-target effects. Taken together,
these consistent findings suggest that HSP70/HSC70 plays an im-
portant beneficial role in the HAZV replication cycle that is inde-
pendent of the native role of HSP70/HSC70 in host cell processes.
An important question that we now wish to ask is this: at
what stage of the nairovirus replication cycle is HSP70/HSC70
acting, such that it is essential for virus production? The finding
that PIF and VER both cause a dramatic reduction in the accu-
mulation of N protein at nontoxic concentrations suggests that
HSC70/HSP70 likely influences one or more early stages of the
replication cycle prior to, or including, protein production,
such as virus entry, uncoating, RNA synthesis, or protein syn-
thesis. The packaging of these chaperones in association with
RNPs within a secreted, infectious particle is also consistent
with an early role in the viral replication cycle, when RNPs are
released from the virion into the cytosol. Possible roles include
facilitating RNP conformational changes that may be required
for dissociation of RNPs from the glycoprotein endodomains
and decondensation of RNPs in preparation for primary tran-
scription. Interestingly, a role for HSP70/HSC70 in early RNP
functions has been proposed for canine distemper virus (48),
another negative-stranded RNA virus. Those authors sug-
gested that HSP70/HSC70 could be required for remodeling of
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the RNP template, perhaps from a condensed to a more relaxed
conformation, and that this switch may be needed for gene
expression. However, HSP70 family members and their associ-
ated DnaJ cofactors may play important proviral roles in more
than one stage of the nairovirus life cycle. Dependence on the
HSP70/DnaJ chaperone network at all stages of the dengue
virus 2 (DENV-2) replication cycle was recently comprehen-
sively dissected, assigning defined roles to multiple HSP70 iso-
forms and DnaJ protein combinations (47). That work revealed
an important role for cytosolic cofactor DnaJ A2 during DENV
RNA replication, and, interestingly, this factor was detected in
the MS analysis of precipitated CCHFV N, also consistent with
a role in nairovirus RNA replication. It is also noteworthy that
the DnaJ B11 cofactor found to be required for DENV assembly
was the sole DnaJ cofactor found in HAZV particles, also sug-
gestive of the possibility that members of the HSP70/DnaJ net-
work represent proviral cell factors that are required across
diverse virus families.
In regard to the role of the N-HSP70 interaction, it has
previously been shown that heat shock proteins rescue the abil-
ity of mutant proteins to adopt a native conformation (49). In
the context of RNA viruses, this ability may be particularly
beneficial with respect to mitigating the consequences of their
high genome mutation rates, which could otherwise result in
the generation of pools of misfolded viral proteins. It has been
suggested that large multisubunit complexes that depend on
the precise geometry of interacting components may be partic-
ularly vulnerable to protein misfolding, as a single misfolded
subunit may render the entire complex defective (50). In the
case of the negative-stranded RNA viruses such as nairoviruses,
they possess RNP complexes built from multiple copies of N
protein in association with the RNA genome, as well as an
associated polymerase. The nairovirus L segment is over 12,000
nucleotides long and is likely encapsidated by over 1,000 N
protein monomers that enwrap the long L segment RNA. It is
feasible that the nairoviruses may have developed a strategy
involving cellular chaperones to protect this significant meta-
bolic investment in the face of frequent polymerase error. A
better understanding of critical virus-host cell interactions
such as the N-HSP70 interaction may aid in the design of ef-
fective strategies for control of pathogenic viruses within the
Nairovirus genus, as well as of other related viruses. This may be
particularly promising in the case of heat shock proteins, as many
of the corresponding inhibitory compounds are well character-
ized and as viruses appear to be unable to develop resistance (51).
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